Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana
- PMID: 36014368
- PMCID: PMC9412417
- DOI: 10.3390/molecules27165119
Investigation of the N-Glycosylation of the SARS-CoV-2 S Protein Contained in VLPs Produced in Nicotiana benthamiana
Abstract
The emergence of the SARS-CoV-2 coronavirus pandemic in China in late 2019 led to the fast development of efficient therapeutics. Of the major structural proteins encoded by the SARS-CoV-2 genome, the SPIKE (S) protein has attracted considerable research interest because of the central role it plays in virus entry into host cells. Therefore, to date, most immunization strategies aim at inducing neutralizing antibodies against the surface viral S protein. The SARS-CoV-2 S protein is heavily glycosylated with 22 predicted N-glycosylation consensus sites as well as numerous mucin-type O-glycosylation sites. As a consequence, O- and N-glycosylations of this viral protein have received particular attention. Glycans N-linked to the S protein are mainly exposed at the surface and form a shield-masking specific epitope to escape the virus antigenic recognition. In this work, the N-glycosylation status of the S protein within virus-like particles (VLPs) produced in Nicotiana benthamiana (N. benthamiana) was investigated using a glycoproteomic approach. We show that 20 among the 22 predicted N-glycosylation sites are dominated by complex plant N-glycans and one carries oligomannoses. This suggests that the SARS-CoV-2 S protein produced in N. benthamiana adopts an overall 3D structure similar to that of recombinant homologues produced in mammalian cells.
Keywords: COVID; N-glycans; Nicotiana benthamiana; SPIKE; biologics; biopharmaceuticals; mass spectrometry; plant molecular farming; vaccine.
Conflict of interest statement
G.P.L. declares that he is a named inventor on granted patent WO 29087391 A1 which describes the HyperTrans expression system and associated pEAQ vectors used for the expression of the SARS-CoV-2 S protein. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
Figures





Similar articles
-
Analysis of the N-glycosylation profiles of the spike proteins from the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2.Anal Bioanal Chem. 2023 Aug;415(19):4779-4793. doi: 10.1007/s00216-023-04771-y. Epub 2023 Jun 24. Anal Bioanal Chem. 2023. PMID: 37354227 Free PMC article.
-
Deducing the N- and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2.Glycobiology. 2020 Dec 9;30(12):981-988. doi: 10.1093/glycob/cwaa042. Glycobiology. 2020. PMID: 32363391 Free PMC article.
-
Stabilization of the Metastable Pre-Fusion Conformation of the SARS-CoV-2 Spike Glycoprotein through N-Linked Glycosylation of the S2 Subunit.Viruses. 2024 Jan 31;16(2):223. doi: 10.3390/v16020223. Viruses. 2024. PMID: 38399999 Free PMC article.
-
Site-Specific O-glycosylation of SARS-CoV-2 Spike Protein and Its Impact on Immune and Autoimmune Responses.Cells. 2024 Jan 5;13(2):107. doi: 10.3390/cells13020107. Cells. 2024. PMID: 38247799 Free PMC article. Review.
-
Site-specific glycosylation of SARS-CoV-2: Big challenges in mass spectrometry analysis.Proteomics. 2022 Aug;22(15-16):e2100322. doi: 10.1002/pmic.202100322. Epub 2022 Jun 22. Proteomics. 2022. PMID: 35700310 Free PMC article. Review.
Cited by
-
Dimming the corona: studying SARS-coronavirus-2 at reduced biocontainment level using replicons and virus-like particles.mBio. 2024 Dec 11;15(12):e0336823. doi: 10.1128/mbio.03368-23. Epub 2024 Nov 12. mBio. 2024. PMID: 39530689 Free PMC article. Review.
-
Tailored Viral-like Particles as Drivers of Medical Breakthroughs.Int J Mol Sci. 2024 Jun 18;25(12):6699. doi: 10.3390/ijms25126699. Int J Mol Sci. 2024. PMID: 38928403 Free PMC article. Review.
-
Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells.Commun Med (Lond). 2023 Aug 23;3(1):116. doi: 10.1038/s43856-023-00340-7. Commun Med (Lond). 2023. PMID: 37612423 Free PMC article.
-
Fine-tuning the N-glycosylation of recombinant human erythropoietin using Chlamydomonas reinhardtii mutants.Plant Biotechnol J. 2024 Nov;22(11):3018-3027. doi: 10.1111/pbi.14424. Epub 2024 Jul 5. Plant Biotechnol J. 2024. PMID: 38968612 Free PMC article.
-
Plants as Biofactories for Therapeutic Proteins and Antiviral Compounds to Combat COVID-19.Life (Basel). 2023 Feb 23;13(3):617. doi: 10.3390/life13030617. Life (Basel). 2023. PMID: 36983772 Free PMC article. Review.
References
-
- Wang D., Zhou B., Keppel T.R., Solano M., Baudys J., Goldstein J., Finn M., Fan X., Chapman A., Bundy J., et al. N-glycosylation profiles of the SARS-CoV-2 spike D614G mutant and its ancestral protein characterized by advanced mass spectrometry. Sci. Rep. 2021;11:23561. doi: 10.1038/s41598-021-02904-w. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous